Neon Therapeutics is a clinical-stage immuno-oncology company and specializes in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. It develops therapies that target abnormal proteins called neoantigens, which are produced by cancer cells. Its programs are designed to leverage multiple facets of the immune response to elicit potent immune attack of tumors, with the aim of providing durable response to patients in need.
|Access Industries, Wellington Management, Third Rock Ventures, Hillhouse Capital Group, Casdin Capital, Nextech Invest, Fidelity Management and Research Company, Clal Biotechnology Industries, Inbio Ventures, Partner Fund Management, ArrowMark Partners|
When was Neon Therapeutics founded?
Neon Therapeutics was founded in 2015.
Who are Neon Therapeutics key executives?
Neon Therapeutics's key executives are Hugh ODowd, Ed Fritsch and Richard Gaynor.
How many employees does Neon Therapeutics have?
Neon Therapeutics has 71 employees.
Who are Neon Therapeutics competitors?
Competitors of Neon Therapeutics include BC Cancer, Asian Institute of Medical Sciences and Genetron Health.
Where is Neon Therapeutics headquarters?
Neon Therapeutics headquarters is located at 40 Erie St #110, Cambridge.
Where are Neon Therapeutics offices?
Neon Therapeutics has an office in Cambridge.
How many offices does Neon Therapeutics have?
Neon Therapeutics has 1 office.
Receive alerts for 300+ data fields across thousands of companies